Immunosuppressants drugs - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.76 [0.65, 0.87]< 114%23 studies (23/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %lownot evaluable highcrucial-
deaths 0.81 [0.75, 0.88]< 14%34 studies (34/-)100.0 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.76 [0.60, 0.95]< 134%7 studies (7/-)99.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.71 [0.52, 0.98]< 161%10 studies (10/-)98.2 %some concerncritical moderateimportant-
clinical improvement 1.22 [1.11, 1.34]> 19%12 studies (12/-)100.0 %some concernlow moderateimportant-
clinical improvement (14-day) 1.31 [1.13, 1.52]> 10%3 studies (3/-)100.0 %lownot evaluable highimportant-
clinical improvement (28-day) 1.33 [0.95, 1.87]> 10%4 studies (4/-)95.3 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.14 [1.03, 1.27]> 10%4 studies (4/-)99.4 %some concernnot evaluable moderateimportant-
death or ventilation 0.83 [0.77, 0.91]< 118%13 studies (13/-)100.0 %some concernlow moderateimportant-
hospital discharge 1.05 [0.88, 1.25]> 113%2 studies (2/-)70.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.81 [0.70, 0.93]< 11%9 studies (9/-)99.8 %some concernnot evaluable moderateimportant-
ICU admission 0.85 [0.49, 1.49]< 157%3 studies (3/-)71.2 %some concernnot evaluable moderatenon important-
recovery 1.30 [0.64, 2.66]> 19%2 studies (2/-)76.5 %some concernnot evaluable moderatenon important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.94 [0.78, 1.13]< 10%10 studies (10/-)74.7 %some concerncritical moderateimportant-
superinfection 0.50 [0.32, 0.79]< 10%1 study (1/-)99.8 %lownot evaluable highimportant-
adverse events 1.32 [0.92, 1.91]< 157%9 studies (9/-)6.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.